Healthcare AI Local Validation: A Practical Plan Before a Workflow Goes Live

Author: Eunoia Consulting Co. | Published: October 20, 2026

A practical healthcare AI local-validation plan for defining intended use, evaluating local workflow conditions, testing representative cases, setting human-review expectations, measuring meaningful evidence and deciding whether a pilot should proceed, change or pause.

A healthcare AI vendor may offer validation material, product documentation and confident performance claims. Those inputs can be useful. They do not answer every question about whether a particular organisation can use a feature in its own workflow, with its own data, users, interfaces and escalation paths.

Local validation is the disciplined work of checking whether a defined AI-enabled workflow operates as intended in the setting where it will actually be used. It does not require a healthcare organisation to recreate a manufacturer’s study or make a blanket judgment about every AI product. It requires leaders to define the use, assess the local conditions that can change meaning or risk, test the workflow proportionately and document the decision.

This is an operational framework, not medical, legal, privacy, security or regulatory advice. The appropriate level of review depends on the use case, the role of the output, the data involved and the consequences of error.

Begin with the local use statement

A local validation plan starts before a test is selected. Write a clear statement that names the user, workflow step, output, decision role, data inputs, setting and limits of use.

For example, “Use an AI assistant to draft a patient-access call summary for staff review” is more precise than “use AI for patient access.” The first statement identifies a draft, a human reviewer and a defined workflow. It makes it possible to test completeness, accuracy, hand-off quality and review burden. It also makes out-of-scope use visible.

Include these questions:

• What task is the tool intended to support?
• Who may use the output, and who is accountable for review or override?
• What data enters and leaves the workflow?
• What action can the output influence?
• Which people, settings or cases are not in scope?
• What change would require the organisation to revisit this statement?

The National Institute of Standards and Technology describes its AI Risk Management Framework as voluntary guidance intended to help organisations incorporate trustworthiness considerations into the design, development, use and evaluation of AI systems. Its Govern, Map, Measure and Manage functions offer a useful organising pattern; they are not a certification or a substitute for local professional judgement. Review the NIST AI RMF.

Match the evidence to the decision

Validation evidence should answer a defined decision, not merely collect documents. Start by separating three layers of evidence.

First, review what the vendor says about the product, version, intended use, known limitations, performance, data, security and support. Second, consider whether those claims are relevant to the organisation’s population, workflow, interfaces, configuration and human-review process. Third, gather local observations from a controlled test.

The resulting decision record should make it possible for a future reviewer to understand what was considered, what was not known and what conditions remained open. That is more useful than a folder of unchecked documentation.

For AI or predictive algorithms included in certified health IT, the ASTP/ONC HTI-1 Final Rule establishes algorithm-transparency requirements within the Health IT Certification Program. It provides a defined certification context in which clinical users can access a baseline set of information to support assessments of fairness, appropriateness, validity, effectiveness and safety. That rule should not be represented as approval of every local AI deployment. It does, however, reinforce the value of asking what information users can actually access about an algorithm before relying on it. Read the HTI-1 Final Rule overview.

Build a proportionate test plan

The test plan should fit the use case. A low-consequence administrative drafting aid does not need the same review depth as an AI-enabled intervention that can influence clinical decision making. In both cases, the plan should define the target workflow, the scenarios to test, the expected result, the reviewer, the evidence captured and the decision route.

Choose representative scenarios rather than only easy examples. Include normal cases, incomplete inputs, edge conditions, changed source information, hand-off points and conditions where the system is unavailable. If the product is expected to handle a population or workflow segment, make sure the test set reflects that use rather than a convenient sample.

The FDA’s Good Machine Learning Practice materials address the development of AI/ML-enabled medical devices and emphasise a total-product-life-cycle perspective. That device-focused guidance is not a universal local-validation rule. It is a useful reminder that intended use, data, testing, human factors and change matter together rather than as isolated checkboxes. Read FDA’s GMLP guiding principles.

Test the workflow, not only the output

A technically plausible output can still fail operationally. Test the full sequence around it:

• What source information is available when the tool runs?
• How is the output displayed, delivered or incorporated into work?
• Who reviews it and what can that reviewer change?
• What happens if the output is incomplete, unclear or inconsistent with source information?
• How is the correction recorded, routed or learned from?
• What is the fallback when the tool or an interface is unavailable?

Ask users to perform the work in a realistic setting. A configuration that works in a vendor demonstration may create duplicate documentation, hidden queues, confusing hand-offs or unmanageable alerts in a live process. The goal is not to make the tool pass at all costs. It is to discover the conditions under which the workflow is usable, unsuitable or needs more evidence.

Define measures that lead to a decision

There is no universal metric set for healthcare AI. Define measures according to the stated job. A documentation draft may be assessed for factual consistency with source material, review effort, omission types, usability and escalation frequency. A workflow-routing feature may be assessed for correct routing, timeliness, manual correction, exception patterns and impact on queue visibility.

Use a baseline when it is meaningful. Compare the AI-assisted workflow with the existing method, not an idealised process. Note what was not measured and why. Avoid using a single accuracy figure to make a broad suitability claim when it does not reflect the local workflow, population or decision consequence.

Where relevant, make the measure definitions explicit. What counts as an error? Who classifies it? Which source is authoritative? What level of disagreement requires review? What does the organisation do if a concerning pattern appears? Clear definitions improve both the test and the next review.

Make human oversight concrete

“Human in the loop” is not a control unless people know what they are expected to do. A usable review design names the reviewer, the point of review, source information available, allowed action, escalation route and conditions that require bypass or pause.

Training should cover more than button clicks. Users need to understand the intended use, common limitations, what not to do, how to identify an exception and who receives a concern. Test the escalation route during the pilot. A procedure that has never been used can be difficult to rely on when a real issue occurs.

Document whether the output is advisory, draft-only, routing support or something else. Do not allow the actual workflow to expand beyond the approved use because a tool is convenient or because users assume that a confident-looking output is authoritative.

Include change control before go-live

A local validation is not permanent. A material change to the model, feature, configuration, data source, integration, user group or intended use can alter the relevance of earlier evidence.

Record the version or configuration tested, the date, the vendor materials reviewed, the local conditions, open issues, approval conditions and next review trigger. Define who receives a change notice and who decides whether a targeted re-test is needed. The goal is to avoid discovering months later that a major dependency changed without anyone connecting it to the original decision.

For a companion process that carries evidence into procurement, see Eunoia’s healthcare AI procurement evidence register. For organisation-wide operating controls, explore AI governance advisory.

Use four clear pilot decisions

A local test should end with a documented choice:

• Proceed as defined: the available evidence supports use within the stated scope.
• Proceed with conditions: the workflow may continue only while named actions, training, monitoring or documentation conditions are completed.
• Modify and re-test: a material issue requires a change before routine use.
• Pause or do not proceed: the current workflow is not acceptable for the proposed use.

The decision should identify the accountable owner, evidence reviewed, limitations, unresolved issues and next review date. That is not bureaucracy for its own sake. It helps an organisation keep the same facts visible when the feature, workflow or evidence changes.

Build a validation practice that teams can use

Healthcare AI validation becomes manageable when it is tied to a specific workflow, a usable record and clear ownership. The best first plan is often small enough to be used next week, then improved after the team sees what the real workflow requires.

Eunoia Consulting Co. helps healthcare organisations define AI use cases, validation questions, workflow tests and accountable review paths before a new capability becomes operationally dependent. Explore AI governance services or contact our team to discuss a focused validation plan for a defined workflow.

Sources

• National Institute of Standards and Technology: AI Risk Management Framework
• ASTP/ONC: HTI-1 Final Rule
• U.S. Food and Drug Administration: Good Machine Learning Practice Guiding Principles